Tag Archives | mayo clinic study

Thalidomide may delay the need for chemotherapy in some patients

A Mayo Clinic study is the first to show that for some patients with early stage multiple myeloma, the drug thalidomide may effectively delay the need for chemotherapy or more aggressive treatment for as much as two years. Multiple myeloma is an incurable cancer of the bone marrow. The final results of the nonrandomized phase II clinical trial were published today in the April issue of the journal Leukemia. Because of the promising indications, preliminary findings were released about a year ago.

Survival rates of anorexia sufferers, non-sufferers differ little

A long-term study of patients in Rochester, Minn., with the eating disorder anorexia nervosa found that their survival rates did not differ from the expected survival rates of others of the same age and sex. The results, published in the March issue of Mayo Clinic Proceedings, add to the knowledge of anorexia nervosa and point to other areas that need greater study from researchers. “Although our data suggest that overall mortality is not increased among community patients with anorexia nervosa in general, these findings should not lead to complacency in clinical practice because deaths do occur,” says L. Joseph Melton, III, M.D., Mayo Clinic epidemiologist and an author of the report.

Most Golf 'Yippers' Perceive Symptoms as Physical, Not Psychological

Over one-half of golfers affected by the “yips” report symptoms that strongly suggest a physical rather than psychological origin of the problem, according to findings of a Mayo Clinic study published in the most recent issue of Sports Medicine. The ‘yips’ is a condition that involves a tremor, freezing or involuntary jerking of the hands when attempting golf shots, particularly short putts. Previous research has indicated it adds nearly five strokes to an affected golfer’s 18-hole score.

Loss of Mental, Functional Abilities Not Guaranteed for Those in 90s

A new Mayo Clinic study shows that the fears of many related to living into one’s 90s and beyond — getting lost in your own neighborhood; losing the ability to take care of financial affairs; having a driver’s license revoked; ending up in a nursing home — are in many cases unfounded. This research, to be published in the Feb. 11 issue of Neurology, demonstrates that for many age 90 and above, memory can be strikingly sharp even up to one century of age.

Sleep apnea may be a cause, rather than just an effect, of heart failure

An interruption in normal breathing patterns during sleep which is often seen in heart failure patients may contribute to heart failure rather than just being a result, according to findings of a Mayo Clinic study.
“We are now finding that central sleep apnea, which has been previously understood as a symptom of heart failure, may contribute to the development of heart failure in people at risk,” said the study’s lead researcher.

Abnormal Number of Chromosomes is One Step in Cancer Development

Researchers have produced the first laboratory evidence to show that a cell’s possession of an abnormal numbers of chromosomes contributes to the development of cancers. Their report on the role of this chromosomal instability, known as aneuploidy, appears in today’s online edition of the Feb. 3 Journal of Cell Biology. Because 85 percent of human cancer cells possess an abnormal number of chromosomes, researchers have long been curious about the role of aneuploidy in the multistep cancer process.

Thalidomide for multiple myeloma patients may lengthen survival

Nearly one-third of patients with advanced multiple myeloma who had failed current standard therapy of chemotherapy or stem cell transplantation responded to thalidomide for a median duration of nearly one year in a Mayo Clinic study of the effects of thalidomide on myeloma. The findings are reported in the January issue of Mayo Clinic Proceedings.
Many studies in the last three years have determined that thalidomide is effective in the treatment of multiple myeloma, following the initial report by researchers at the University of Arkansas. However, information is limited on how long thalidomide therapy works and on survival rates with such therapy.

Interleukin-6 May Lead to Drugs That Prevent Brain Injury From Diseases, Aging

A Mayo Clinic investigation of Interleukin-6, a hormone inside cells often considered a “bad actor” of the immune system because of its association with inflammation injuries and malignant diseases, shows that it also plays a therapeutic role in mice: it protects brain cells. Interleukin-6 — called IL-6 for short by researchers — may, in fact, be a “white knight” for mouse brain cells, or neurons, as brain cells also are called. These results, while early, may be promising for humans as well. The Mayo Clinic investigation is described in the Jan. 15 Journal of Neuroscience.

One in Four have Precursor to Heart Failure

More than one-fourth of adults over age 45 have abnormalities in the way their heart fills with blood and are at significantly increased risk for premature death, according to results of a study of 2,042 randomly selected residents of Olmsted County, Minn. The study is published in the Jan. 8 issue of the Journal of the American Medical Association (JAMA).

No Difference Between Ionized Bracelet and Placebo for Pain Relief

Researchers from the Mayo Clinic say that wearing ionized bracelets for the treatment of muscle and joint pain is no more effective than wearing placebo bracelets. Authors of the published study randomly assigned 305 participants to wear an ionized bracelet for 28 days and another 305 participants to wear a placebo bracelet for the same duration. The study volunteers were men and women 18 and older who had self-reported musculoskeletal pain at the beginning of the study. Neither the researchers nor the participants knew which volunteers wore an ionized bracelet and which wore a placebo bracelet. Bracelets were worn according to the manufacturer’s recommendations. Both types of bracelets were identical and were supplied by the manufacturer, QT, Inc.